Appointments

Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

Study of ARN-810 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Status: Recruiting
Phase: Phase 1
Diagnosis: Breast: Metastatic
NCT ID: NCT01823835 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-043

 

Safety and pharmacokinetics (PK) study of ARN-810 in postmenopausal women with locally advanced or metastatic ER+ (HER2-) breast cancer.

 

Conducting Institutions:
Massachusetts General Hospital

Overall PI:
Aditya Bardia MD, MPH, Massachusetts General Hospital

Site-responsible Investigators:

Contacts:
Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100

Eligibility Criteria

Key Inclusion Criteria: 1. Histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of either locally recurrent disease not amenable to resection or radiation therapy with curative intent, or metastatic disease, both progressing after at least 6 months of hormonal therapy for ER+ breast cancer 2. ER-positive, HER2-negative 3. At least 2 months must have elapsed from the use of tamoxifen 4. At least 6 months must have elapsed from the use of fulvestrant 5. At least 2 weeks must have elapsed from the use of any other anti-cancer hormonal therapy 6. At least 4 weeks must have elapsed from the use of any chemotherapy 7. Females, 18 years of age or older 8. Postmenopausal status 9. Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2 Key Exclusion Criteria: 1. Untreated or symptomatic CNS metastases. 2. Endometrial disorders 3. More than 1 prior chemotherapy in the advanced/metastatic setting (prior adjuvant chemotherapy is allowed so long as it occurred ≥ 12 months prior to enrollment) 4. Current treatment with any systemic anti-cancer therapies for advanced disease or any systemic experimental treatment on another clinical trial
  •   Email
  •   Print
  •   Share
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients


    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online
dana farber logo

450 Brookline Avenue
Boston, MA 02215

Call us toll-free: 866-408-DFCI (3324)

Connect with us
award

Dana-Farber/Brigham and Women’s Cancer Center is ranked #4 nationally and the best in New England.

award

Dana-Farber/Boston Children's is ranked the #1 pediatric cancer center.

Sign-up for newsletters